10:36 AM
 | 
Sep 28, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Alexion eyes submissions for Soliris in rare CNS disease

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) plans to submit regulatory applications in the U.S., EU and Japan for Soliris eculizumab to treat relapsing neuromyelitis optica spectrum disorder (NMOSD) after the drug met the primary endpoint in the Phase III PREVENT trial in the indication.

The company told BioCentury it is too soon to speculate on specific timing, but said it plans to discuss the data with regulators and prepare submissions as quickly as possible.

NMOSD is a rare complement-mediated disorder of the CNS that...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >